Ambrohexal, 3 mg/ml syrup 100 ml

Ambrohexal is a drug with mucolytic, secretolytic and expectorant action, and the active ingredient of the drug is ambroxol. The mechanism of action of this drug is associated with reduction of sputum viscosity as a result of depolymerization of sputum mucopolysaccharides, which consists in breaking disulfide bonds in molecules, increasing the release of active hydrolyzing enzymes from Clark cells.

Ambrohexal also increases the activity of the cilia of the bronchial epithelium, and normalizes the ratio of all components of sputum and in this regard stimulates its mucociliary transport. This facilitates expectoration of sputum from the respiratory tract and stimulates secretion and blockage of surfactant breakdown.

Ambrohexal is rapidly absorbed from the gastrointestinal tract with high absorption capacity, and its optimal plasma concentration is reached within two hours after taking the drug: tablets, syrup, sustained release capsules and inhalation solution.

The action of the drug starts after 30 minutes after taking the syrup or tablets and depends on the speed of absorption of the drug in the stomach and intestines. The drug is metabolized in the liver, where it is converted to dobromanthranilic acid and glucuronic conjugates and excreted by the kidneys.

Indications

Acute, bronchitis with sputum retention, pneumoconiosis, bronchial asthma, tuberculosis and cystic fibrosis, bronchiectatic disease, acute pneumonia, pleurisy, emphysema, acute, prolonged and chronic sinusitis, chronic rhinitis.

Active ingredient

How to take, the dosage

Ingestion.

Adults and children over 12 years of age – 1 scoop (5 ml) 3 times a day for the first 2-3 days, then 1 scoop (5 ml) 2 times a day.

Children:

In children under 2 years of age Ambrohexal® is prescribed only under medical supervision.

Interaction

Concomitant use with anti-cough drugs leads to difficulty of expectoration of sputum against the background of suppression of the cough reflex. It increases penetration into the bronchial secretion of amoxicillin, cefuroxime, erythromycin and doxycycline.

Special Instructions

In case of impaired bronchial motility and increased amount of secretion (e.g. immobile cilia syndrome) due to the danger of mucus accumulation, the drug may only be taken after consultation with the attending physician and under medical supervision. In severe renal or hepatic impairment, lower concentrations should be used or the interval between doses should be increased.

Hint for patients with diabetes mellitus: 1 scoop (5 ml syrup) contains 2.525 g sorbitol (0.21 IU).

Contraindications

With caution, the drug should be used in patients with peptic ulcer disease and duodenal ulcer disease, because the aggravation of the ulcer may occur, as well as in patients with renal and hepatic failure, pregnancy (II-III trimester).

Side effects

Overdose

Pregnancy use

Similarities